The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | What are the next steps for CAR-T in myeloma?
Sham Mailankody, MBBS, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the future of CAR-T and cellular therapy for multiple myeloma patients. With no currently approved CAR-T therapy for myeloma, he hopes a major advancement will be FDA approval of a BCMA-targeted CAR-T therapy in the near future. With regards to upcoming trials and research, there will be a focus on next-generation BCMA CAR T-cells, as well as newer targets such as GPRC5D and CD38. Trials of CAR-T-based combination therapies are being to be designed, as well as off the shelf CAR-T and CAR-NK treatments that may overcome the limitations of current therapies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
